HHS · Notice · Rel 100 (Federal Register (major agencies))
Regulatory Considerations for Prescription Drug Use-Related Software; Guidance for Industry; Availability
Other · Health / life sciences · general, public-health, fda-guidance
Source summary
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Regulatory Considerations for Prescription Drug Use-Related Software." This final guidance describes FDA's application of its drug labeling authorities to certain software outputs that are disseminated by or on behalf of a drug sponsor for use with a prescription drug product or a prescription drug-led, drug-device combination product that is assigned to the Center for Drug Evaluation and Research or the Center for Biologics Evaluation and Research as the lead center. This guidance finalizes the draft guidance of the same title issued on September 19, 2023.
Analyst note
HHS published an official item relevant to other. Use the source link to verify scope before advising clients.
Public reaction (Reddit)
Insufficient public reaction to score sentiment.